Alkahest is developing lead clinical candidates, GRF6019 and GRF6021, as potential treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. Designed to safely replenish regenerative positive chronokines that decrease with age, GRF6019 and GRF6021 are highly selected human plasma fractions that provide enhancement of cognition and motor activity, reduction of inflammation and restoration of neurogenesis.
GRF6019 is currently being studied in a Phase 2 trial for the treatment of mild to moderate Alzheimer’s disease. GRF6021 entered a Phase 2 trial in 2018 for the treatment of Parkinson’s disease, with support from The Michael J. Fox Foundation (MJFF). GRF6019 will soon be tested in a second indication, severe Alzheimer’s disease.
GRF6019 and GRF6021, proprietary plasma fractions, are developed and provided by Grifols in partnership with Alkahest. Grifols is one of the world’s largest producers of plasma derived medicines.
Debbie Wallace, Corporate Controller